Search - tctmd.com

Displaying 281 - 300 of 524

Sort: Relevancy | Date

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Opinion CV Team Dispatch

May 2022 News Roundup

L.A. McKeown

May 01, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Michael O'Riordan

April 22, 2022

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Caitlin E. Cox

April 15, 2022

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

L.A. McKeown

April 08, 2022

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

Todd Neale

April 08, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

Presentation ACC 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presenter: Tariq Ahmad

April 04, 2022

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

L.A. McKeown

April 03, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Opinion CV Team Dispatch

April 2022 News Roundup

L.A. McKeown

April 01, 2022

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Opinion CV Team Dispatch

March 2022 News Roundup

L.A. McKeown

March 01, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

L.A. McKeown

February 07, 2022

News Conference News STS 2022

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Michael O'Riordan

February 04, 2022

Advertisement

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

May 2022 News Roundup

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 2022 News Roundup

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

Guideline-Directed Therapies Underused in Frail HF Patients

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

March 2022 News Roundup

FDA Approves Empagliflozin for Treatment of HFpEF

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content